Abstracts tagged "osteophytosis and synovitis"

Abstract Number: 771 • 2013 ACR/ARHP Annual Meeting
The S100A9 Inhibitor Paquinimod (ABR-215757) Reduces Synovial Activation, Osteophyte Formation and Cartilage Damage In Experimental Osteoarthritis
Rik Schelbergen¹, Arjen B. Blom¹, Tomas Leanderson², Helena Eriksson³, Wim B. van den Berg⁴ and Peter L.E.M. van Lent¹, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Immunology Group, Lund University, Lund, Sweden, ³BioScience, Active Biotech AB, Lund, Sweden, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Synovial activation is present in a large subset of osteoarthritis (OA) patients and it is thought to play an important role in the development…
Abstract Number: 46 • 2013 ACR/ARHP Annual Meeting
Alarmins S100A8/A9 Regulate Osteophyte Formation In Experimental Osteoarthritis With High Synovial Activation
Rik Schelbergen¹, Arjen B. Blom¹, Wouter de Munter¹, Annet W. Sloetjes², Thomas Vogl³, Johannes Roth⁴, Wim B. van den Berg⁵ and Peter L.E.M. van Lent¹, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, ³Institute of Immunology, University of Muenster, Muenster, Germany, ⁴Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁵Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Osteophytes are cartilage capped, bony outgrowths that limit joint movement and originate from the periosteum or from ligaments during osteoarthritis (OA). There is increasing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].